Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Bisphosphonate in Stress Fracture Treatment -A Randomised Controlled Double Blinded Multicenter Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-70 years~* Stress fractures in the foot. A stress fracture is defined as a fracture occured after repetitive trauma, with characteristic MRI findings (ref) and distinctive pain over the fracture site at weight bearing.~* at least 6 months of pain history~* compliant patient~* non-aided ambulatory patient prior to the injury~Exclusion Criteria:~* Ongoing use of bisphosphonates, PTH/PTH-analogues or use within 12 months prior to the injury~* Use of bisphophonates for more than 6 months within the last 5 years~* Intolerance to zoledronic acid~* Renal failure (GFR\<30)~* S-25(OH)vitD \> 25~* pregnancy~* breast feeding~* hypocalcemia~* MRI contraindications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Zoledronic Acid Injectable Product (Type: ACTIVE_COMPARATOR): Patients randomized to treatment with Zoledronic Acid 5mg infusion, repeated after 3 months
- Placebo (Type: PLACEBO_COMPARATOR): Patients randomized to Placebo infusion (saline), repeated after 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).